Effect of Nephropathy Prescription I on the Expression of Angptl3 and Podocyte-Associated Protein in Mice with Adriamycin-Induced Nephropathy

Author:

Zhang Feifei1,Liu Junchao1,Yu Jian1ORCID,Sun Wen1,Wang Yonghong1,Fan Teng1,Sun Yanyan1,Han Xinghui1

Affiliation:

1. Children's Hosptial of Fudan University Department of Traditional Chinese Medicine, Shanghai 201102, China

Abstract

Objective. This study aimed to investigate the effects of Nephropathy Prescription I on the expression of angptl3, nephrin, and podocin, in addition to its protective effects on podocytes in mice with adriamycin-induced nephropathy. Methods. BALB/c mice were randomly divided into the control (C), adriamycin (Model or M), adriamycin + Nephropathy Prescription I (M + Z), adriamycin + prednisone acetate (M + S), and adriamycin + Nephropathy Prescription I + prednisone acetate groups (M + Z + S). All mice except those in the C group in the experimental groups were treated with a single tail vein injection of adriamycin. The urine albumin-creatinine ratio was measured before model establishment and on the 7th day, 14th day, 21st day, and 28th day of doxorubicin injection. All the mice were sacrificed on the 29th day. Blood samples were collected to observe biochemical indicators in the serum. The morphological structure and podocyte ultrastructure in the kidney were observed using light and electron microscopy, respectively. The expression of angptl3, nephrin, and podocin at the mRNA and protein levels was detected by real-time PCR and western blotting, respectively. Results. Following modeling with adriamycin, albuminuria was observed in urine samples in the first week, and the urinary protein/creatinine ratio increased maximally in the fourth week in the M group ( P < 0.05 ). In contrast, the urinary protein/creatinine ratio significantly decreased ( P < 0.05 ) in the third week in the (M + Z) group compared to that in the M group. Similarly, this ratio decreased in the (M + S) and (M + Z + S) groups compared to that in the M group throughout the experiment. Compared with the C group, serum albumin content and the expression of nephrin and podocin decreased ( P < 0.05 ), whereas blood lipid level and the expression of angptl3 increased ( P < 0.05 ) in the M group. Glomerular foot process fusion was observed in this group using electron microscopy. In all the intervention groups, serum albumin content and the expression of nephrin and podocin increased ( P < 0.05 ), whereas blood lipid level and the expression of angptl3 decreased ( P < 0.05 ), with alleviated glomerular foot process injury observed particularly in the (M + Z + S) group. Conclusion. The Nephropathy Prescription I can alleviate albuminuria, increase serum albumin levels, lower blood lipid levels, and reduce the fusion of foot processes of podocytes in mice with adriamycin-induced nephropathy. The protective effects of the Nephropathy Prescription I may function by reducing Angptl3 expression and increasing nephrin and podocin expression.

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Reference46 articles.

1. Nephrotic syndrome in childhood

2. Nephrotic syndrome: what's new, what's hot?

3. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy

4. A brief review of several factors affecting alcohol precipitation of traditional Chinese medicine;F.-J. Gao;Shandong traditional Chinese medicine journal,1999

5. Effects of Liuwei Dihuang Decoction and its water and alcohol precipitation extract on cyclic adenosine monophosphate in type 2 diabetic rats with kidney yin deficiency;B. Dai;Chinese Journal of Biological Control,2012

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3